Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antib...
Q1 2027
Aug 10, 2026
FY 2026
May 20, 2026
Q4 2026
Q3 2026
Feb 6, 2026
Q2 2026
Nov 10, 2025
